The ORBITA-CTO trial is the first placebo-controlled, randomized study assessing CTO PCI efficacy in stable angina patients with single-vessel coronary chronic total occlusion (CTO).
CTO PCI significantly improved daily angina symptom burden, increasing angina-free days by over 30 days versus placebo at 6 months.
Improvements were confirmed across patient-reported outcomes including the Seattle Angina Questionnaire and Canadian Cardiovascular Society class, with blinded assessment maintained.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
